SSRI for Treating Depressed HIV Patients
DESCRIPTION: (Verbatim from the Applicant's Abstract) The goal of this Phase I
SBIR application is to develop a long acting injectable antidepressant for use
in depressed, non-compliant HIV-seropositive individuals. HIV-seropositive
individuals have increased rates of depression and medication non-compliance.
We have developed a synthetic approach for substituting a decanoate moiety on
the free amine of antidepressants resulting in a long acting compound.
Sertraline has certain pharmacokinetic advantages over other antidepressants.
The proposed studies will develop sertraline decanamide as a long acting
antidepressant for parenteral administration. Our Specific Aims are:
Specific Aim 1: Manufacture sufficient sertraline decanamide for proposed
studies. Specific Aim 2: Determine the dose-response curves of sertraline
decanamide (i.m. in oil) and sertraline HCI for inhibiting serotonin uptake by
rat brain synaptosomes after in vivo administration. Specific Aim 3: Determine
the selectivity of sertraline decanamide and sertraline HCI for inhibiting
serotonin uptake in vitro. Concentration-response curves for the in vitro
inhibition of synaptosomal norepinephrine, dopamine and serotonin uptake will
be generated for the two compounds and compared.
Specific Aim 4: Determine the long-term time course (0 to 28 days) for
inhibition of synaptosomal serotonin uptake by sertraline decanamide (i.m. in
oil) and sertraline HCI after a single dose.
PROPOSED COMMERCIAL APPLICATION:
Small Business Information at Submission:
Principal Investigator:James J. Mulchahey
PHASE-TWO DISCOVERY, INC.
3130 HIGHLAND AVE, 3RD FL CINCINNATI, OH 45219
Number of Employees: